Fig. 6.

NRF2 target gene induction in tumors with high NRF2 activity. (A) Gene expression values for NQO1 and HIF1A in bladder carcinoma (BLCA), lung squamous cell carcinoma (LUSC), and lung adenocarcinoma (LUAD). For each cancer, tumors with mutated NRF2 (NRF2^mut) or mutated KEAP1 (KEAP1^mut) were separated from tumors with no mutations in either gene (NRF2^WT; KEAP1^WT). Expression values are based on pan-cancer normalized RNA-seq data from The Cancer Genome Atlas (TCGA); each dot represents expression levels from a single tumor, and horizontal lines represent the mean expression for the cancer/genotype population. Significant changes in NRF2^mut or KEAP1^mut relative to NRF2^WT; KEAP1^WT are indicated (Wilcoxon rank-sum test; ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05) (B) Gene expression values for NQO1 and HIF1A in breast cancer (BRCA) tumors. Tumors with high inferred NRF2 activity were separated from normal tumors based on a 32 gene NRF2 expression signature (see Methods). As in (A), expression values are based on pan-cancer normalized RNA-seq data from TCGA; each dot represents expression levels from a single tumor, and horizontal lines represent the mean expression for each population. Expression in tumors with high inferred NRF2 activity was compared to expression in tumors with normal inferred NRF2 activity, and significant differences are indicated (Wilcoxon rank-sum test; ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05).